Contents

Section-A: Medical Oncology

1. Concepts of Cancer Chemotherapy 3

First Person Dr Paul Ehrlich (20th Century) Used Term Chemotherapy 3

2. Chemotherapeutic Drugs 8

Induction Chemotherapy 8; Adjuvant Chemotherapy 9; Primary Chemotherapy 9; Concomitant Chemoradiotherapy 9; Salvage Chemotherapy 10; Aldesleukin 10; Amifostine 12; Aminoglutethimide 13; Anastrozole 14; Arsenic Trioxide 15; Asparaginase 17; Capecitabine 19; Carboplatin 20; Carmustine 22; Cetuximab 23; Cisplatin 24; Cladribine 26; Corticosteroids 27; Cyclophosphamide 28; Cytarabine 29; Dacarbazine 31; Dactinomycin 32; Daunorubicin, Liposomal 33; Docetaxel 34; Doxorubicin 35; Doxorubicin, Liposomal 37; Epirubicin 38; Epoetin 40; Estrogens 41; Etoposide 42; Filgrastim 43; Fludarabine 44; Fluorouracil 45; Flutamide 47; Fulvestrant 48; Gefitinib 48; Gemcitabine 49; Hydroxyurea 50; Ifosfamide 51; Imatinib Mesylate 53; Interferon-a 54; Irinotecan 56; Letrozole 58; Luteinizing Hormone—Releasing Hormone Analogs 58; Melphalan 59; Mercaptopurine 60; Mesna 61; Methotrexate 62; Mitomycin 63; Mitoxantrone 64; Octreotide 65; Oxaliplatin 66; Paclitaxel 67; Pamidronate 69; Pegfilgrastim 70; Porfimer 71; Procarbazine 72; Progestins 73; Rituximab 74; Sargramostim 76; Suramin 77; Tamoxifen 78; Temozolomide 79; Thalidomide 80; Thiotepa 81; Topotecan 82; Toremifene 83; 131-I-Tositumomab 84; Trastuzumab 85; Vinblastine 86; Vincristine 87; Vinorelbine 88; Zoledronic Acid 89

3. Targeted Cancer Therapy 91

Cancer Biology 91; Mechanisms of Carcinogenesis 91; First Targeted Therapies 98; What is ATRA and ATO? 98; Candidates for Targeted Therapies 98; Alemtuzumab 100

4. New Hope with Gene Therapy 102

Cyclosporine 102; Immunosuppressant Antibodies 102; Approaches in Gene Therapy 102; Applications of Gene Therapy 104

5. Side Effects of Chemotherapy 106

What Causes Side Effects with Chemotherapy? 106; During Chemotherapy Remember These Lines 106; Chemo Agents and its Toxicity 107; Common Side Effects 107; After Effect of Chemotherapy 109

6. Hormone Treatment in Cancer 116

Anterior Pituitary Hormone 116; Hormone Production—How Androgen and Estrogen Produced? 118; Hormone Treatment in Cancer Patients 119; Nonsteroidal Antiestrogenic Drugs 119; Hormone Treatment in Thyroid Cancer 121

Section-B: General Management in Oncology

7. Management of Cancer Pain 125

Types of Neurogenic Cancer Pain 125; Phenytoin Drug 126; The Pain History 127; Pain Intensity Rating Scales 127

8. Management of Anemia 129

Erythropoietine 130; Changes in Health-related QOL Parameters 130; Cancer Therapy Outcomes 130; Dosing Regimens 130; Safety and Tolerability 132; Pharmacoeconomic Considerations 132

9. Management of Bleeding in Cancer Patient's 135

Etiology and Clinical Presentation 135; Physiology of Hemostasis 135; Management: General Measures 135; Management: Local Interventions 137; Management 140

10. Role of Steroids in Cancer 145

How Steroids Help? 145; Side Effects 146

11. Role of Antacids 148

Acid-Related Pathophysiology—The Stomach Secretes 148; Parietal Cells Stimulation Secretion 149

Section-C: Common Cancer and its Management

12. Management of Cervical Cancer 155

Treatment of CIN/dysplasia 155; Treatment of Ca Cervix 155; Management Pretreatment Evaluation 156; Stage IA, Treatment 157; Stage IB1 157; How to Treat Early B1 Lesion by Radiotherapy? 157; Use of Midline Block 157; Radiotherapy 157; Stage IB2/IIA Treatment 159; Stage IIB, III, IVA Treatment 159; Stage IVA Treatment 160; Type of Hystectomy 160; Recurrence of Carcinoma Cervix 161; After Treatment Follow-up of Patients 161; Who Should get this Vaccine? 162; Type of Strain of Virus 162; Why is the HPV Recommended for such Young Girls? 162; Why is the HPV Vaccine Only Recommended for Girls/ Women Ages 9 to 26? 162; Should Pregnant Women get the Vaccine? 162; Efficiency of the HPV Vaccine 162; Why does the Vaccine not Protect Against? 162; Safety of HPV Vaccine 162; Dose Schedule 163

13. Breast Cancer Management 164

Pretreatment Evaluation 164; Early Stage Breast Carcinoma 165; Recommendation for Axillary Lymph Node Radiation 168

14. Palliative Treatment in Breast Cancer 171

Palliative Radiotherapy Indicated in Breast Cancer 171; Brain Secondary 172; Spinal Cord Compression 173; Neoplastic Plexopathy 173

15. Head and Neck Cancer 175

Cancer Oral Cavity 175

16. Ovarian Cancer 187

Incidence 187; Anatomy 187; Lymph Node Metastasis 188; Classification of Ovarian Ca 189; Treatment Options are Surgery and Chemotherapy 191; Chemotherapy 191; Dose Intense Vs Dose Dense 192; Role of Radiotherapy 193

17. Endometrial Cancer 195

Classification 196; Signs and Symptoms 196; Risk Factors 196; Diagnosis and Clinical Evaluation 197; Endometrial Adenocarcinoma 198; Further Evaluation 198; Staging 198; Treatment 199; Complications of Treatment 199; Prognosis 199; Survival Rates 201

18. Hodgkin's Lymphoma 202

Immunophenotype 202; Clinical Presentation 202; Lymphadenopathy 202; Diagnostic Evaluation 203; Ann Arbor Staging Classification 203; Treatment 203

19. Non-Hodgkin's Lymphoma 206

Pathology 206

20. Gallbladder Cancer 214

Artery Supply of Gallbladder 215; Pathology of CAGB 215; Clinical Features 216; Management of CAGB 217; Surgery for Carcinoma of the Gallbladder 217; Complications after Surgery 217; Radiotherapy Role in Gallbladder Cancer 218

21. Lung Cancer 220

Nonsmall Cell Lung Carcinoma (NSCLC) 221; Small Cell Lung Carcinoma (SCLC) 221; Signs and Symptoms 222; CECT Thorax of Lung Cancer 224; Pathogenesis 225; Chemotherapy 227

22. Carcinoma Larynx 230

Indirect Laryngoscopic Mirror View 230; Transglottic Carcinoma 231; Connective Tissue Barriers of the Larynx 231; Premalignant Conditions of Larynx 232; Larynx Blood Supply/Lymphatic Chain/Nerve

Supply 232; Lymphatics of Larynx 232; Nerve Supply 232; Epidemiology/Etiology 232; Risk Factors for Larynx Cancer 232; Other Risk Factor for Ca Larynx 233; Pathology 233; Local and Distant Spread of Larynx Ca 233; Glottic Ca 233; Supraglottic Ca 233; Lymphatic Spread 234; Clinical Presentation 235; Contraindication of D/L Scopy 237; Radiography in Laryngeal Cancer 237; CT Scan 237; Management of Larynx Ca 237; Glottic Ca 237; Ca In Situ 237; Glottic Ca T1/T2 Lesion 237; Glottic Ca T3/T4 Lesion 238; RTOG Phase-III Trial 238; Veterans Affairs Laryngeal Study Group 238; Radiotherapy 238; After Radiotherapy 239; Recurrence 239; Management of Supraglottic Lx 239; Subglottic Ca Larynx 240

23. Nasopharynx Carcinoma (NPC) 241

Nasopharyngeal Tonsil 241; Epidemiology 242; Result of Treatment 246

24. Thyroid Cancer 247

What About Chemotherapy? 249

25. Leukemia 253

Classification 253

26. Neuroendocrine Tumor 261

The neuroendocrine system 261; Metastases and malignancy 266

Section-D: Radiation Oncology

27. Radioactivity 275

Radioactivity 275; Radioactivity by Nuclear Fission 279

28. Measurement of X-ray 282

The Biological Effects—Depends Upon 282; Requirements of X-ray Dosimeter 283; Air is Chosen 283; Other Measuring Methods 284; TLD System of Exposure Measurement 287; Chamber Size 288; Measuring System 288; Wall Thickness 288

29. Principles of Radiation Therapy 291

Movement of Cobalt Machine 293; Concepts of Brachytherapy 297; Ideal Brachytherapy Source 297; Forms of Applications 297; Practical Aspects in Brachytherapy 299; Multiple Sources 300; Interstitial Implant 301; Dose Rate and ICRU-38 Recommendations 304; Day Time PDR 305

30. Time, Dose and Fractionation in Radiotherapy 306

Strandquist Plot and the Ellis Nominal Standard Dose System 307; Ellis Introduced NSD System 307; Weakness of NSD System 307; Proliferation as a Factor in Normal Tissue 307; Dose Response Relation for Early and Late Responding Tissue 308; Responding Tissue 310; Accelerated Repopulation 310;

Multiple Fractions Per Day 311; Hyperfractionation 311; Pure Hyperfractionation 311; Flexure Dose (FD) 311; Accelerated Treatment 312; Chart 312; Time Interval between Multiple Daily Fractions 312; T Pot and Accelerated Treatment 312; Linear Quadratic Concept to Calculate Effective Dose in Radiotherapy 313

31. Effects of Radiation on Normal Human Tissue 314

Acute Effects 314; Early Lethal Effects 315; Radiation 315; Individual Variation 316; Symptoms 316; Acute Radiation Induce Toxicity Profile 317; Management of Acute Radiation Exposure at the Dose Close to LD_{50} 317; Bone Marrow Transplantation (BMT) 318; Complication due to BMT 318

32. Latest Radiotherapy Technique 319

Image-guided Radiation Therapy (IGRT) 319; Intensity-modulated Radiation Therapy (IMRT) 320

33. Imaging in Oncology 323

Treatment Planning and Response Assessment 326

34. Radiation Oncologist with Benign Tumors 328

Ocular Disorder 328; Exophthalmos 328; Orbital Pseudotumor 329; Plantar Warts 329; Desmoid Tumor 330; Prevention of Restenosis after PTCA (Percutaneous Transluminal Coronary Angioplasty) 330; Ameloblastoma of Jaw 331; Aneurysmal Bone Cyst 331; Vertebral Hemangioma 331; Rheumatoid Arthritis 331; Juvenile Nasopharyngeal Angiofibroma 331; Inverted Papilloma 332; Eosinophilic Granuloma LCH 332; Radiotherapy Strongly Advised 332

Bibliography 333

Index 345